THRB and metabolic dysfunction-associated steatohepatitis: In fact, the US Food and Drug Administration recently approved resmetirom, a TRβ-selective agonist, for the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis [4].